Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...

The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its ...

Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Tariff wars and macro woes have impacted investor sentiment, weighing on stocks across various sectors. However, healthcare ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...